


# One-month of dual anti-platelet therapy is safe and feasible after stent placement

16 November 2020



Credit: CC0 Public Domain

A one-month treatment of dual anti-platelet therapy is safe and as effective as a longer duration of therapy at preventing cardiac events in patients one year after stent placement, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.

"This study is the first randomized trial comparing one-year clinical outcomes of one-month of dual anti-platelet [therapy](#) followed by aspirin monotherapy to the currently recommended dual anti-platelet therapy regimen in [patients](#) with [coronary artery disease](#) who are recovering from stent placement," said lead study investigator Myeong-Ki Hong, M.D., Ph.D., professor of cardiology at Yonsei University College of Medicine, Severance Cardiovascular Hospital in Seoul, Korea.

Patients recovering from artery-opening procedures involving a stent are prescribed one or more anti-platelet medications (to help keep platelets from sticking together), typically for months, along with aspirin to prevent blood from

clotting in the stent. This is known as dual anti-platelet therapy. Dual anti-platelet therapy, also known as DAPT, can pose a significant risk of bleeding for patients who are already taking blood thinners.

Most studies evaluating a shorter course of DAPT have focused on patients at high-risk for bleeding. Additionally, many recent studies have also focused on patients receiving a class of antiplatelet known as a P2Y12 inhibitor monotherapy rather than aspirin monotherapy after a shorter course of DAPT.

Researchers in this study evaluated and compared the safety and effectiveness of two durations of dual anti-platelet therapy in patients who had drug-eluting stent placement or polymer-free drug-coated stent placement and were not at a high-risk of bleeding.

Across 23 medical centers in Korea, 3,020 Korean patients (mean age 67; 31% women) were randomly assigned to receive either:

- one-month of dual anti-platelet therapy after polymer-free drug-coated stent [placement](#) followed by 11 months of aspirin alone;
- or 6-12 months duration of anti-platelet therapy followed by 0-6 months of aspirin alone after drug-eluting [stent placement](#) procedure.

Drug-eluting [stents](#) are coated with a polymer that slowly releases medication designed to reduce the risk of the artery reclogging. Polymer-free drug-coated stents are a newer type of stent created to address potential inflammation caused by polymer.

Most of the patients (2,969) completed a one-year follow-up. Analysis found there was no significant difference in the number of cardiac events between the two groups: 5.9% of patients in the one-month treatment group died or had a heart attack, stroke,

major bleeding or stent/ angioplasty procedure, compared to 6.5% in the six- to 12-month treatment group.

"It is encouraging to see that one-month dual anti-platelet therapy, followed by aspirin monotherapy after polymer-free drug-coated stent is effective and safe in a diverse group of patients with coronary artery disease," Hong said. "These results also could lead to the suggestion for some patients to discontinue a P2Y12 inhibitor, rather than [aspirin](#), in daily clinical practice, which could result in better patient compliance, lower costs, a lower risk of bleeding, and overall, more convenience for both patients and physicians."

Provided by American Heart Association

APA citation: One-month of dual anti-platelet therapy is safe and feasible after stent placement (2020, November 16) retrieved 2 June 2022 from <https://medicalxpress.com/news/2020-11-one-month-dual-anti-platelet-therapy-safe.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*